Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00427427 · ClinicalTrials.gov registry record · Phase 2
Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer
A Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT00427427: Clinical Trial Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
NCT00427427 is a Phase 2 study that was terminated before completion, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 75 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00427427, a Phase 2 study, was terminated before completion, sponsored by Jonsson Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of the study is to determine what factors affect a patient's decision to accept delayed Herceptin® treatment after completing their surgery and/or chemotherapy and/or radiation therapy. Women with invasive breast cancer that have a HER-2 positive (FISH +) determination in 2004 or thereafter and who have completed surgery and primary treatment earlier will be potentially eligible. Patients will be asked to complete a questionnaire about their breast cancer and reasons why they may or may not accept Herceptin® treatment. Patients will be given the option to (1) receive Herceptin® for 52 weeks and have annual doctor visits for 5 years or (2) not to receive Herceptin® but agree to annual doctor visits for 5 years.
Interventions
- DRUG Trastuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2007-01 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
Why NCT00427427 stopped before completion
NCT00427427 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower).
The record links to 0 conditions, and to 1 intervention - of which Trastuzumab is the first listed.
NCT00427427 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00427427 about?
NCT00427427 is a clinical study titled "Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer". The purpose of the study is to determine what factors affect a patient's decision to accept delayed Herceptin® treatment after completing their surgery and/or chemotherapy and/or radiation therapy. Women with invasive breast cancer that have a HER-2 positive (FISH +) determination in 2004 or therea...
What is the current status of trial NCT00427427?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2007-01. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00427427?
The interventions under investigation include: Trastuzumab (DRUG).
Who is sponsoring clinical trial NCT00427427?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00427427's enrollment target sits among peer trials
75 900th of 2000 higher than 1,081 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia